Drug – bio-affecting and body treating compositions – Lymphokine
Reexamination Certificate
2007-04-10
2007-04-10
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Lymphokine
C530S324000
Reexamination Certificate
active
10087273
ABSTRACT:
The present invention provides novel nucleic acids, novel polypeptide sequences encoded by these nucleic acids, methods for production thereof, and uses thereof, for a novel ELR-CXC chemokine receptor antagonist.
REFERENCES:
patent: WO 97/00601 (1997-01-01), None
patent: PCT/CA02/00271 (2002-01-01), None
Gordon John R.
Li Fang
Battison Adrian D.
Dupis Ryan W.
Mertz Prema
University of Saskatchewan Technologies Inc.
Williams Michael R.
LandOfFree
High-affinity antagonists of ELR-CXC chemokines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High-affinity antagonists of ELR-CXC chemokines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High-affinity antagonists of ELR-CXC chemokines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3740676